Transgene SA
11 rue de MOLSHEIM, 67082
Strasbourg
Cedex
France
Tel: 011-33-3-88-27-91-21
Fax: 011-33-3-88-27-91-11
Website: http://www.transgene.fr/
327 articles about Transgene SA
-
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®
6/28/2022
Transgene and BioInvent International AB announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.
-
Transgene and BioInvent Announce Positive Progress for BT-001
6/27/2022
Transgene and BioInvent International AB jointly announced positive progress and safety data of the ongoing Phase I/IIa trial evaluating BT-001 in patients with solid tumors, including melanoma.
-
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
-
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
6/6/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it presented updated preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, in a poster session at the American Society of Clinical Oncology annual meeting.
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
5/27/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology annual meeting.
-
Transgene Announces Upcoming Investor Meetings - May 17, 2022
5/17/2022
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events set out below:
-
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
4/8/2022
Transgene will present additional positive immunogenicity and clinical data on TG4050, its individualized neoantigen cancer vaccine.
-
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
3/31/2022
Transgene announces today that, as part of the evolution of its corporate governance, the Board of Directors has proposed Alessandro Riva, MD, as Chairman of the Company. If this nomination is accepted by Company shareholders at the upcoming General Shareholder Meeting, the Board intends to appoint Dr. Riva to the position of Chairman.
-
Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022
3/16/2022
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2021 and provides an update on its product pipeline.
-
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
3/9/2022
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with new and promising preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, at the AACR Annual Meeting 2022.
-
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
3/9/2022
Transgene and BioInvent International AB jointly announce that an abstract reporting preclinical studies of BT-001, a novel oncolytic virus, has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting 2022.
-
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
-
Transgene Appoints Steven Bloom as Chief Business Officer
2/10/2022
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that it has appointed Steven Bloom as Vice President, Chief Business Officer with immediate effect.
-
BioInvent & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade
1/20/2022
BioInvent International AB and Transgene jointly announce the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.
-
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
1/20/2022
Transgene and BioInvent International AB jointly announced the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.
-
Transgene Announces Investor Meetings for January 2022
12/17/2021
Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
12/15/2021
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca has exercised its first license option for an Invir.IO™ oncolytic virus developed from their on-going OV collaboration.
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
11/9/2021
BioInvent International AB and Transgene announce preclinical data supporting the mode of action of BT-001, their novel dual mechanism-of-action oncolytic Vaccinia Virus.